Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for argenex (ARGX : NSDQ)

• Company Description    argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. Number of Employees: 650

• Price / Volume Information    Yesterday's Closing Price: $319.97 Daily Weekly Monthly 20 Day Moving Average: 405,037 shares Shares Outstanding: 53.62 (millions) Market Capitalization: $17,156.47 (millions) Beta: 1.11 52 Week High: $356.78 52 Week Low: $249.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.30% 14.10% 12 Week 12.13% 23.27% Year To Date -8.63% 11.64%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Willemstraat 5 - Breda,P7 4811 AH NLD ph: 31-0-10-703-8441 fax: - info@argenx.com http://www.argenx.com

• General Corporate Information    Officers Tim Van Hauwermeiren - Chief Executive Officer Peter K.M. Verhaeghe - Chairperson Werner Lanthaler - Vice Chairperson Pamela Klein - Director A.A. Rosenberg - Director Peer Information argenex (CORR.) argenex (RSPI) argenex (CGXP) argenex (BGEN) argenex (GTBP) argenex (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04016X101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 53.62 Most Recent Split Date: (:1) Beta: 1.11 Market Capitalization: $17,156.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-4.81 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-19.44 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 3.22% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.52 Price/Cash Flow: - Price / Sales: 42.52 EPS Growth vs. Year Ago Period: -438.27% vs. Previous Quarter: 8.40% Sales Growth vs. Year Ago Period: -81.20% vs. Previous Quarter: -29.79% ROE 03/31/22 - -32.54 12/31/21 - -22.33 09/30/21 - -23.86 ROA 03/31/22 - -29.44 12/31/21 - -20.20 09/30/21 - -20.10 Current Ratio 03/31/22 - - 12/31/21 - 8.44 09/30/21 - - Quick Ratio 03/31/22 - - 12/31/21 - 8.08 09/30/21 - - Operating Margin 03/31/22 - -147.47 12/31/21 - -75.69 09/30/21 - -73.28 Net Margin 03/31/22 - -147.47 12/31/21 - -75.69 09/30/21 - -73.28 Pre-Tax Margin 03/31/22 - - 12/31/21 - -74.11 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - 49.05 09/30/21 - - Inventory Turnover 03/31/22 - - 12/31/21 - 0.00 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.00 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - 0.00 09/30/21 - -

Powered by Zacks Investment Research ©